Thomas Wekerle

List of Publications by Year
in descending order

166 papers	6,213 citations	101496 36 h-index	79644 73 g-index
170 all docs	170 docs citations	170 times ranked	4494 citing authors

#	Article	IF	Citations
1	Costimulation Blockade with Belatacept in Renal Transplantation. New England Journal of Medicine, 2005, 353, 770-781.	13.9	827
2	Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment. Nature Medicine, 2000, 6, 464-469.	15.2	491
3	Extrathymic T Cell Deletion and Allogeneic Stem Cell Engraftment Induced with Costimulatory Blockade Is Followed by Central T Cell Tolerance. Journal of Experimental Medicine, 1998, 187, 2037-2044.	4.2	328
4	Five-Year Safety and Efficacy of Belatacept in Renal Transplantation. Journal of the American Society of Nephrology: JASN, 2010, 21, 1587-1596.	3.0	177
5	The influence of immunosuppressive drugs on tolerance induction through bone marrow transplantation with costimulation blockade. Blood, 2003, 101, 2886-2893.	0.6	169
6	Mixed Chimerism and Transplantation Tolerance. Annual Review of Medicine, 2001, 52, 353-370.	5.0	162
7	Mechanisms of transplant tolerance induction using costimulatory blockade. Current Opinion in Immunology, 2002, 14, 592-600.	2.4	158
8	Strategies for long-term preservation of kidney graft function. Lancet, The, 2017, 389, 2152-2162.	6.3	147
9	MIXED CHIMERISM AS AN APPROACH FOR THE INDUCTION OF TRANSPLANTATION TOLERANCE1. Transplantation, 1999, 68, 459-467.	0.5	133
10	Treg-Therapy Allows Mixed Chimerism and Transplantation Tolerance Without Cytoreductive Conditioning. American Journal of Transplantation, 2010, 10, 751-762.	2.6	127
11	Belatacept-Based Immunosuppression in De Novo Liver Transplant Recipients: 1-Year Experience From a Phase II Randomized Study. American Journal of Transplantation, 2014, 14, 1817-1827.	2.6	121
12	Long-Term Outcomes in Belatacept- Versus Cyclosporine-Treated Recipients of Extended Criteria Donor Kidneys: Final Results From BENEFIT-EXT, a Phase III Randomized Study. American Journal of Transplantation, 2016, 16, 3192-3201.	2.6	116
13	Peripheral Deletion After Bone Marrow Transplantation with Costimulatory Blockade Has Features of Both Activation-Induced Cell Death and Passive Cell Death. Journal of Immunology, 2001, 166, 2311-2316.	0.4	110
14	ANTI-CD154 OR CTLA4Ig OBVIATES THE NEED FOR THYMIC IRRADIATION IN A NON-MYELOABLATIVE CONDITIONING REGIMEN FOR THE INDUCTION OF MIXED HEMATOPOIETIC CHIMERISM AND TOLERANCE1. Transplantation, 1999, 68, 1348-1355.	0.5	108
15	The Role of Non-Deletional Tolerance Mechanisms in a Murine Model of Mixed Chimerism with Costimulation Blockade. American Journal of Transplantation, 2005, 5, 1237-1247.	2.6	91
16	Transplantation tolerance through mixed chimerism. Nature Reviews Nephrology, 2010, 6, 594-605.	4.1	87
17	Costimulatory pathways in transplantation. Seminars in Immunology, 2011, 23, 293-303.	2.7	80
18	Early regulation of CD8 T cell alloreactivity by CD4+CD25- T cells in recipients of anti-CD154 antibody and allogeneic BMT is followed by rapid peripheral deletion of donor-reactive CD8+ T cells, precluding a role for sustained regulation. European Journal of Immunology, 2005, 35, 2679-2690.	1.6	72

#	Article	IF	Citations
19	Combination of Extended Donor Criteria and Changes in the Model for End-Stage Liver Disease Score Predict Patient Survival and Primary Dysfunction in Liver Transplantation: A Retrospective Analysis. Transplantation, 2007, 83, 588-592.	0.5	72
20	IDO and Regulatory T Cell Support Are Critical for Cytotoxic T Lymphocyte-Associated Ag-4 Ig-Mediated Long-Term Solid Organ Allograft Survival. Journal of Immunology, 2012, 188, 37-46.	0.4	72
21	Mechanisms Involved in the Establishment of Tolerance Through Costimulatory Blockade and BMT: Lack of Requirement for CD40L-Mediated Signaling for Tolerance or Deletion of Donor-reactive CD4+ Cells. American Journal of Transplantation, 2001, 1, 339-349.	2.6	71
22	Tolerance in mixed chimerism â€“ a role for regulatory cells?. Trends in Immunology, 2004, 25, 518-523.	2.9	70
23	Belatacept: from rational design to clinical application. Transplant International, 2012, 25, 139-150.	0.8	66
24	Past, present, and future of allergen immunotherapy vaccines. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 131-149.	2.7	66
25	Toward MSC in Solid Organ Transplantation: 2008 Position Paper of the MISOT Study Group. Transplantation, 2009, 88, 614-619.	0.5	64
26	Earlier Low-Dose TBI or DST Overcomes CD8+ T-Cell-Mediated Alloresistance to Allogeneic Marrow in Recipients of Anti-CD40L. American Journal of Transplantation, 2004, 4, 31-40.	2.6	62
27	Effect of Ex Vivoâ€“Expanded Recipient Regulatory T Cells on Hematopoietic Chimerism and Kidney Allograft Tolerance Across MHC Barriers in Cynomolgus Macaques. Transplantation, 2017, 101, 274-283.	0.5	61
28	Costimulation Blockade Inhibits Allergic Sensitization but Does Not Affect Established Allergy in a Murine Model of Grass Pollen Allergy. Journal of Immunology, 2007, 178, 3924-3931.	0.4	54
29	Prophylactic Bisphosphonate Treatment Prevents Bone Fractures After Liver Transplantation. American Journal of Transplantation, 2007, 7, 1763-1769.	2.6	52
30	Short-Term Immunosuppression Facilitates Induction of Mixed Chimerism and Tolerance after Bone Marrow Transplantation without Cytoreductive Conditioning. Transplantation, 2005, 80, 237-243.	0.5	49
31	Strategies to overcome the ABO barrier in kidney transplantation. Nature Reviews Nephrology, 2015, 11, 732-747.	4.1	49
32	Blocking antibodies induced by immunization with a hypoallergenic parvalbumin mutant reduce allergic symptoms in a mouse model of fish allergy. Journal of Allergy and Clinical Immunology, 2017, 139, 1897-1905.e1.	1.5	48
33	The DESCARTES-Nantes survey of kidney transplant recipients displaying clinical operational tolerance identifies 35 new tolerant patients and 34 almost tolerant patients. Nephrology Dialysis Transplantation, 2016, 31, 1002-1013.	0.4	46
34	T-regulatory cell treatment prevents chronic rejection of heart allografts in a murine mixed chimerism model. Journal of Heart and Lung Transplantation, 2014, 33, 429-437.	0.3	45
35	Anti-CD154 mAb and Rapamycin Induce T Regulatory Cell Mediated Tolerance in Rat-to-Mouse Islet Transplantation. PLoS ONE, 2010, 5, e10352.	1.1	42
36	Mechanisms of tolerance induction through the transplantation of donor hematopoietic stem cells: central versus peripheral tolerance. Transplantation, 2003, 75, 21S-25S.	0.5	39

#	Article	IF	Citations
37	Transplantation Tolerance through Hematopoietic Chimerism: Progress and Challenges for Clinical Translation. Frontiers in Immunology, 2017, 8, 1762.	2.2	39
38	Short-Term Effects of High-Dose Zoledronic Acid Treatment on Bone Mineralization Density Distribution After Orthotopic Liver Transplantation. Calcified Tissue International, 2008, 83, 167-175.	1.5	38
39	Tolerization of a Type I Allergic Immune Response through Transplantation of Genetically Modified Hematopoietic Stem Cells. Journal of Immunology, 2008, 180, 8168-8175.	0.4	38
40	Treg-mediated prolonged survival of skin allografts without immunosuppression. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 13508-13516.	3.3	38
41	Minimal conditioning required in a murine model of T cell depletion, thymic irradiation and high-dose bone marrow transplantation for the induction of mixed chimerism and tolerance. Transplant International, 2002, 15, 248-253.	0.8	34
42	T regulatory cells in xenotransplantation. Xenotransplantation, 2009, 16, 121-128.	1.6	34
43	CTLA4Ig Promotes the Induction of Hematopoietic Chimerism and Tolerance Independently of Indoleamine-2,3-Dioxygenase. Transplantation, 2007, 83, 663-667.	0.5	32
44	Oncolytic influenza A virus expressing interleukin-15 decreases tumor growth inÂvivo. Surgery, 2017, 161, 735-746.	1.0	31
45	Clinical validation of a novel enzyme-linked immunosorbent spot assay-basedinÂvitrodiagnostic assay to monitor cytomegalovirus-specific cell-mediated immunity in kidney transplant recipients: a multicenter, longitudinal, prospective, observational study. Transplant International, 2018, 31, 436-450.	0.8	30
46	Rapid Deletional Peripheral CD8 T Cell Tolerance Induced by Allogeneic Bone Marrow: Role of Donor Class II MHC and B Cells. Journal of Immunology, 2008, 181, 4371-4380.	0.4	29
47	Mixed chimerism through donor bone marrow transplantation. Current Opinion in Organ Transplantation, 2012, 17, 63-70.	0.8	29
48	CTLA4-Ig immunosuppressive activity at the level of dendritic cell/T cell crosstalk. International Immunopharmacology, 2013, 15, 638-645.	1.7	28
49	Separate regulation of peripheral hematopoietic and thymic engraftment. Experimental Hematology, 1998, 26, 457-65.	0.2	28
50	Role of peripheral clonal deletion in tolerance induction with bone marrow transplantation and costimulatory blockade. Transplantation Proceedings, 1999, 31, 680.	0.3	27
51	Therapeutic Efficacy of Polyclonal Tregs Does Not Require Rapamycin in a Low-Dose Irradiation Bone Marrow Transplantation Model. Transplantation, 2011, 92, 280-288.	0.5	27
52	Rapamycin and CTLA4Ig Synergize to Induce Stable Mixed Chimerism Without the Need for CD40 Blockade. American Journal of Transplantation, 2015, 15, 1568-1579.	2.6	27
53	Macrophage Depletion Prolongs Discordant but not Concordant Islet Xenograft Survival. Transplantation, 2005, 79, 543-549.	0.5	26
54	The Immunosuppressive Effect of CTLA4 Immunoglobulin Is Dependent on Regulatory T Cells at Low But Not High Doses. American Journal of Transplantation, 2016, 16, 3404-3415.	2.6	26

#	Article	IF	Citations
55	Recent Progress in Tolerance Induction through Mixed Chimerism. International Archives of Allergy and Immunology, 2007, 144, 254-266.	0.9	24
56	T-Regulatory Cellsâ€"What Relationship With Immunosuppressive Agents?. Transplantation Proceedings, 2008, 40, S13-S16.	0.3	23
57	Targeting apoptosis to induce stable mixed hematopoietic chimerism and long-term allograft survival without myelosuppressive conditioning in mice. Blood, 2013, 122, 1669-1677.	0.6	23
58	Inflammatory response and oxidative stress during liver resection. PLoS ONE, 2017, 12, e0185685.	1.1	23
59	Tailoring of the lung to overcome size disparities in lung transplantation. Journal of Heart and Lung Transplantation, 1996, 15, 239-42.	0.3	23
60	Anti-CD154 mAb Treatment But Not Recipient CD154 Deficiency Leads to Long-Term Survival of Xenogeneic Islet Grafts. American Journal of Transplantation, 2005, 5, 1021-1031.	2.6	22
61	Resistance to ABT-737 in activated T lymphocytes: molecular mechanisms and reversibility by inhibition of the calcineurinâ€"NFAT pathway. Cell Death and Disease, 2012, 3, e299-e299.	2.7	22
62	Comparison Between C0 And C2 Monitoring in De Novo Renal Transplant Recipients: Retrospective Analysis of a Single-Center Experience. Transplantation, 2004, 78, 1787-1791.	0.5	21
63	Recombinant allergen and peptide-based approaches for allergy prevention by oral tolerance. Seminars in Immunology, 2017, 30, 67-80.	2.7	20
64	Prospective Tracking of Donor-Reactive T-Cell Clones in the Circulation and Rejecting Human Kidney Allografts. Frontiers in Immunology, 2021, 12, 750005.	2.2	20
65	Stable prodrugs of n-butyric acid: suppression of T cell alloresponses in vitro and prolongation of heart allograft survival in a fully allogeneic rat strain combination. Transplant Immunology, 1999, 7, 221-227.	0.6	19
66	The advantage of allocating kidneys from old cadaveric donors to old recipients: a single-center experience. Clinical Transplantation, 2006, 20, 471-475.	0.8	19
67	Resistance of parvalbumin to gastrointestinal digestion is required for profound and longâ€lasting prophylactic oral tolerance. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 326-335.	2.7	19
68	Incidence and outcome of major non-pulmonary surgical procedures in lung transplant recipients. European Journal of Cardio-thoracic Surgery, 1997, 12, 718-723.	0.6	18
69	Downsizing of the donor lung: Peripheral segmental resections and lobar transplantation. Transplantation Proceedings, 1997, 29, 2899-2900.	0.3	18
70	Tolerance through bone marrow transplantation with costimulation blockade. Transplant Immunology, 2002, 9, 125-133.	0.6	18
71	Effect of intraportal infusion of tacrolimus on ischaemic reperfusion injury in orthotopic liver transplantation: a randomized controlled trial. Transplant International, 2011, 24, 912-919.	0.8	18
72	Allograft rejection is associated with development of functional IgE specific for donor MHC antigens. Journal of Allergy and Clinical Immunology, 2019, 143, 335-345.e12.	1.5	18

#	Article	IF	Citations
73	Mixed chimerism for the induction of tolerance: potential applicability in clinical composite tissue grafting. Transplantation Proceedings, 1998, 30, 2708-2710.	0.3	17
74	The critical role of mouse CD4+ cells in the rejection of highly disparate xenogeneic pig thymus grafts. Xenotransplantation, 2000, 7, 129-137.	1.6	17
75	Distinctive Expression of Bcl-2 Factors in Regulatory T Cells Determines a Pharmacological Target to Induce Immunological Tolerance. Frontiers in Immunology, 2016, 7, 73.	2.2	17
76	Combining Adoptive Treg Transfer with Bone Marrow Transplantation for Transplantation Tolerance. Current Transplantation Reports, 2017, 4, 253-261.	0.9	17
77	Inducing Mixed Chimerism and Transplantation Tolerance Through Allogeneic Bone Marrow Transplantation With Costimulation Blockade. Methods in Molecular Biology, 2007, 380, 391-403.	0.4	17
78	Lung Transplantation for Primary Pulmonary Hypertension and Giant Pulmonary Artery Aneurysm. Annals of Thoracic Surgery, 1998, 65, 825-827.	0.7	16
79	Transplantation of Discordant Xenogeneic Islets Using Repeated Therapy with Anti-CD154. Transplantation, 2005, 79, 1545-1552.	0.5	16
80	Murine Mobilized Peripheral Blood Stem Cells Have a Lower Capacity than Bone Marrow to Induce Mixed Chimerism and Tolerance. American Journal of Transplantation, 2008, 8, 2025-2036.	2.6	16
81	Mechanistic and therapeutic role of regulatory T cells in tolerance through mixed chimerism. Current Opinion in Organ Transplantation, 2010, 15, 725-730.	0.8	16
82	Bcl-2 Inhibition to Overcome Memory Cell Barriers in Transplantation. American Journal of Transplantation, 2014, 14, 333-342.	2.6	16
83	Regulatory T Cells Promote Natural Killer Cell Education in Mixed Chimeras. American Journal of Transplantation, 2017, 17, 3049-3059.	2.6	16
84	Incomplete clonal deletion as prerequisite for tissue-specific minor antigen tolerization. JCI Insight, 2016, 1, e85911.	2.3	16
85	Lung retransplantation: institutional report on a series of twenty patients. Journal of Heart and Lung Transplantation, 1996, 15, 182-9.	0.3	16
86	Transplantation tolerance induced by mixed chimerism. Journal of Heart and Lung Transplantation, 2001, 20, 816-823.	0.3	15
87	Induction of tolerance. Surgery, 2004, 135, 359-364.	1.0	15
88	Anti-LFA-1 or rapamycin overcome costimulation blockade-resistant rejection in sensitized bone marrow recipients. Transplant International, 2013, 26, 206-218.	0.8	14
89	Long-term outcome of belatacept therapy in de novo kidney transplant recipients - a case-match analysis. Transplant International, 2015, 28, 820-827.	0.8	14
90	Belatacept treatment for twoÂyr after liver transplantation is not associated with operational tolerance. Clinical Transplantation, 2015, 29, 85-89.	0.8	14

#	Article	IF	Citations
91	Cell Therapy for Prophylactic Tolerance in Immunoglobulin E-mediated Allergy. EBioMedicine, 2016, 7, 230-239.	2.7	14
92	Anti-Interleukin-6 Promotes Allogeneic Bone Marrow Engraftment and Prolonged Graft Survival in an Irradiation-Free Murine Transplant Model. Frontiers in Immunology, 2017, 8, 821.	2.2	14
93	Allograft and patient survival after sequential HSCT and kidney transplantation from the same donorâ€"A multicenter analysis. American Journal of Transplantation, 2019, 19, 475-487.	2.6	14
94	Cell-Based Therapy in Allergy. Current Topics in Microbiology and Immunology, 2011, 352, 161-179.	0.7	13
95	Persistent molecular microchimerism induces longâ€term tolerance towards a clinically relevant respiratory allergen. Clinical and Experimental Allergy, 2012, 42, 1282-1292.	1.4	13
96	CTLA4-Ig Preserves Thymus-Derived T Regulatory Cells. Transplantation, 2014, 98, 1158-1164.	0.5	13
97	IL-2 / Î±-IL-2 Complex Treatment Cannot Be Substituted for the Adoptive Transfer of Regulatory T cells to Promote Bone Marrow Engraftment. PLoS ONE, 2016, 11, e0146245.	1.1	13
98	Minimal conditioning required in a murine model of T cell depletion, thymic irradiation and high-dose bone marrow transplantation for the induction of mixed chimerism and tolerance. Transplant International, 2002, 15, 248-253.	0.8	13
99	Transection Speed and Impact on Perioperative Inflammatory Response â€“ A Randomized Controlled Trial Comparing Stapler Hepatectomy and CUSA Resection. PLoS ONE, 2015, 10, e0140314.	1.1	13
100	Modulating T-cell costimulation as new immunosuppressive concept in organ transplantation. Current Opinion in Organ Transplantation, 2012, Publish Ahead of Print, 368-75.	0.8	12
101	Polyclonal Recipient nTregs Are Superior to Donor or Third-Party Tregs in the Induction of Transplantation Tolerance. Journal of Immunology Research, 2015, 2015, 1-9.	0.9	12
102	Induction of Mixed Chimerism through Transplantation of CD45-Congenic Mobilized Peripheral Blood Stem Cells after Nonmyeloablative Irradiation. Biology of Blood and Marrow Transplantation, 2006, 12, 284-292.	2.0	11
103	Kidney Transplantation With Corticosteroids Alone After Haploidentical HSCT From The Same Donor. Transplantation, 2016, 100, 2219-2221.	0.5	11
104	A B Cell Epitope Peptide Derived from the Major Grass Pollen Allergen Phl p 1 Boosts Allergen-Specific Secondary Antibody Responses without Allergen-Specific T Cell Help. Journal of Immunology, 2017, 198, 1685-1695.	0.4	11
105	Janus kinase-3 (JAK3) inhibition: a novel immunosuppressive option for allogeneic transplantation. Transplant International, 2004, 17, 481-489.	0.8	10
106	Indoleamine 2,3-Dioxygenase in Hematopoietic Stem Cell Transplantation. Current Drug Metabolism, 2007, 8, 267-272.	0.7	10
107	Hurdles to the Induction of Tolerogenic Mixed Chimerism. Transplantation, 2009, 87, S79-S84.	0.5	10
108	The role of natural killer T cells in costimulation blockade-based mixed chimerism. Transplant International, 2010, 23, 1179-1189.	0.8	10

#	Article	IF	Citations
109	Belatacept and Tregs: friends or foes?. Immunotherapy, 2012, 4, 351-354.	1.0	10
110	Donor CD4 T Cells Trigger Costimulation Blockade-Resistant Donor Bone Marrow Rejection Through Bystander Activation Requiring IL-6. American Journal of Transplantation, 2014, 14, 2011-2022.	2.6	10
111	Belatacept/CTLA4Ig: an update and critical appraisal of preclinical and clinical results. Expert Review of Clinical Immunology, 2018, 14, 583-592.	1.3	10
112	Hybrid resistance to parental bone marrow grafts in nonlethally irradiated mice. American Journal of Transplantation, 2019, 19, 591-596.	2.6	10
113	A Prospective Controlled Trial to Evaluate Safety and Efficacy of in vitro Expanded Recipient Regulatory T Cell Therapy and Tocilizumab Together With Donor Bone Marrow Infusion in HLA-Mismatched Living Donor Kidney Transplant Recipients (Trex001). Frontiers in Medicine, 2020, 7, 634260.	1.2	10
114	In vivo Treg expansion under costimulation blockade targets early rejection and improves long-term outcome. American Journal of Transplantation, 2021, 21, 3765-3774.	2.6	10
115	Deletional and regulatory mechanisms coalesce to drive transplantation tolerance through mixed chimerism. European Journal of Immunology, 2015, 45, 2470-2479.	1.6	9
116	New approaches to prevent transplant rejection: Co-stimulation blockers anti-CD40L and CTLA4Ig. Drug Discovery Today: Therapeutic Strategies, 2006, 3, 41-47.	0.5	8
117	Combining Treg therapy with mixed chimerism. Chimerism, 2010, 1, 26-29.	0.7	8
118	Dipeptidyl peptidase IV (DPPIV/CD26) inhibition does not improve engraftment of unfractionated syngeneic or allogeneic bone marrow after nonmyeloablative conditioning. Experimental Hematology, 2012, 40, 97-106.	0.2	8
119	Murine models of transplantation tolerance through mixed chimerism: advances and roadblocks. Clinical and Experimental Immunology, 2017, 189, 181-189.	1.1	8
120	Hematopoietic chimerism and tolerance of T cells, B cells, and NK cells. Transplantation Proceedings, 1998, 30, 4020.	0.3	7
121	Molecular signature of mice T lymphocytes following tolerance induction by allogeneic BMT and CD40-CD40L costimulation blockade. Transplant International, 2006, 19, 146-157.	0.8	7
122	A Chimerism-Based Approach to Induce Tolerance in IgE-Mediated Allergy. Critical Reviews in Immunology, 2009, 29, 379-397.	1.0	7
123	Engraftment of retrovirally transduced Bet v 1-GFP expressing bone marrow cells leads to allergen-specific tolerance. Immunobiology, 2013, 218, 1139-1146.	0.8	7
124	The site of allergen expression in hematopoietic cells determines the degree and quality of tolerance induced through molecular chimerism. European Journal of Immunology, 2013, 43, 2451-2460.	1.6	7
125	Immunosenescence Does Not Abrogate Engraftment of Murine Allogeneic Bone Marrow. Transplantation, 2013, 95, 1431-1438.	0.5	7
126	T Cell Subsets Predicting Belatacept-Resistant Rejection: Finding the Root Where the Trouble Starts. American Journal of Transplantation, 2017, 17, 2235-2237.	2.6	7

#	Article	IF	Citations
127	Janus kinase-3 (JAK3) inhibition: a novel immunosuppressive option for allogeneic transplantation. Transplant International, 2004, 17, 481-489.	0.8	6
128	Expression of a Major Plant Allergen as Membrane-Anchored and Secreted Protein in Human Cells with Preserved T Cell and B Cell Epitopes. International Archives of Allergy and Immunology, 2011, 156, 259-266.	0.9	6
129	No augmentation of indoleamine 2,3-dioxygenase (IDO) activity through belatacept treatment in liver transplant recipients. Clinical and Experimental Immunology, 2018, 192, 233-241.	1.1	6
130	CTLA4Ig Improves Murine iTreg Induction via TGFÎ² and Suppressor Function In Vitro. Journal of Immunology Research, 2018, 2018, 1-10.	0.9	6
131	Bone marrow transplantation as a strategy for tolerance induction in the clinic. Frontiers in Bioscience - Landmark, 2009, Volume, 611.	3.0	6
132	Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. European Surgery - Acta Chirurgica Austriaca, 2004, 36, 205-206.	0.3	5
133	Influence of immunosuppressive drugs on cell-induced graft tolerance. Current Opinion in Organ Transplantation, 2004, 9, 307-313.	0.8	5
134	Distinct roles for major and minor antigen barriers in chimerismâ€based tolerance under irradiationâ€free conditions. American Journal of Transplantation, 2021, 21, 968-977.	2.6	5
135	Management of severe bronchial after bilateral sequential lung transplantation. Annals of Thoracic Surgery, 1992, 54, 1221-1222.	0.7	4
136	Intrahepatic splenic tissue in a patient with recurrent idiopathic thrombocytopenic purpura. Surgery, 1998, 123, 596-599.	1.0	4
137	Phylogenetic disparity influences the predominance of direct over indirect pathway of antigen presentation in islet xenotransplantation. Transplantation Proceedings, 2005, 37, 463-465.	0.3	4
138	No Evidence for Recipient-Derived Hepatocytes in Serial Biopsies of Sex-Mismatched Liver Transplants. Transplantation, 2012, 94, 953-957.	0.5	4
139	Minor Antigen Disparities Impede Induction of Long Lasting Chimerism and Tolerance through Bone Marrow Transplantation with Costimulation Blockade. Journal of Immunology Research, 2016, 2016, 1-9.	0.9	4
140	Immune tolerance in transplantation. Clinical and Experimental Immunology, 2017, 189, 133-134.	1.1	4
141	Methods to Detect MHC-Specific IgE in Mice and Men. Frontiers in Immunology, 2020, 11, 586856.	2.2	4
142	Mixed hematopoietic chimerism and transplantation tolerance: insights from experimental models. Current Opinion in Organ Transplantation, 1999, 4, 44.	0.8	4
143	Taming the ABO barrier in transplantation. Blood, 2013, 122, 2527-2528.	0.6	3
144	Effects of Reduced-Dose Anti-Human T-Lymphocyte Globulin on Overall and Donor-Specific T-Cell Repertoire Reconstitution in Sensitized Kidney Transplant Recipients. Frontiers in Immunology, 2022, 13, 843452.	2.2	3

#	Article	IF	Citations
145	Differential expression of circulating miRNAs after alemtuzumab induction therapy in lung transplantation. Scientific Reports, 2022, 12, 7072.	1.6	3
146	Induction of alloantigen-specific hyporesponsiveness in vitro by n-butyrate: antagonistic effect of cyclosporin A. Transplant International, 1996, 9, S318-S322.	0.8	2
147	C2 versus C0 Cyclosporine Monitoring: The End for Us. Transplantation, 2005, 80, 543-544.	0.5	2
148	Role of CD40-CD154 pathway in the rejection of concordant and discordant xenogeneic islets. Transplantation Proceedings, 2005, 37, 460-462.	0.3	2
149	Blockade of adhesion molecule lymphocyte functionâ€“associated antigen-1 improves long-term heart allograft survival in mixed chimeras. Journal of Heart and Lung Transplantation, 2018, 37, 1119-1130.	0.3	2
150	Off to New Horizons. Transplant International, 2005, 18, 1-1.	0.8	1
151	Next level. Transplant International, 2007, 21, 1-1.	0.8	1
152	Molecular chimerism in IgE-mediated allergy. Chimerism, 2013, 4, 29-31.	0.7	1
153	Regulatory Cell Therapy in Kidney Transplantation: Promise Not Yet Fulfilled. Transplantation, 2020, 104, 2262-2263.	0.5	1
154	Transplant International adopts the policy of a uniform clinical trial registration. Transplant International, 2005, 18, 893-893.	0.8	0
155	Full speed ahead. Transplant International, 2006, 19, 1-1.	0.8	0
156	On course. Transplant International, 2007, 20, 1-1.	0.8	0
157	Raising the benchmark. Transplant International, 2009, 22, 143-143.	0.8	0
158	Surgical research â€“ quo vadis?. European Surgery - Acta Chirurgica Austriaca, 2010, 42, 111-111.	0.3	0
159	Continuous improvement. Transplant International, 2011, 24, 1-1.	0.8	0
160	25 and going strong. Transplant International, 2012, 25, 1-1.	0.8	0
161	Antiâ€<scp>OX</scp>40L alone or in combination with antiâ€<scp>CD</scp>40L and <scp>CTLA</scp>4Ig does not inhibit the humoral and cellular response to a major grass pollen allergen. Clinical and Experimental Allergy, 2016, 46, 354-364.	1.4	0
162	1575. Clinical Validation of a Novel ELISpot-based in vitro Diagnostic Assay to Monitor CMV-Specific Cell-Mediated Immunity in SOT and HSCT Immunocompromised Patients. Open Forum Infectious Diseases, 2018, 5, S491-S492.	0.4	0

#	Article	IF	Citations
163	Blocking CD40/CD40L for Chimerism-based Tolerance: Lost in Translation?. Transplantation, 2019, 103, 10-12.	0.5	0
164	Strategies for the Induction of Allograft Tolerance. , 2001, , 127-151.		0
165	Impact of Graft-Resident Leucocytes on Treg Mediated Skin Graft Survival. Frontiers in Immunology, 2021, 12, 801595.	2.2	0
166	Inducing Mixed Chimerism and Transplantation Tolerance Through Allogeneic Bone Marrow Transplantation With Costimulation Blockade. , 0, , 391-404.		0